AstraZeneca, Daiichi Sankyo and ENHERTU

Investors are awaiting the company's fourth-quarter results, scheduled for February 6, for an update on the China issue.
Astra is due to pay Daiichi US$175 million in milestones after the US approval, the companies said. Enhertu is cleared in the ...
Approval of Enhertu marks the first HER2-directed therapy indicated for adults with unresectable or metastatic HR-positive, ...
The AstraZeneca PLC ADR AZN rallied 1.48% to $70.08 Monday, on what proved to be an all-around mixed trading session for the ...
MULTINATIONAL pharmaceutical firm AstraZeneca (AZ) wants to conduct the majority of its clinical trials in the Philippines, ...
AstraZeneca invests $570 million in Canada, expands facilities, and boosts R&D efforts, aiming to deliver 20 new medicines ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
AstraZeneca, a leading multinational pharmaceutical and biotechnology company, has been recognized as the second-best place ...
Haematologist Dr Sue Pavord was one of the jab’s biggest supporters, but she knew something was wrong when she saw the ...